

Lung Cancer Clinical Trials

UCI 14-25


Plasma Exosome Concentration
in Cancer Patients Undergoing
Treatment (Nelson)

UCI 15-79

Ph II Open-Label Randomized
Radiosurgery w/ or w/o TT Fields
for 1-10 Brain Metastases from
NSCLC (Carrillo)

UC 16-01 –SUSPENDED–

Pathway Analyses for Individualized Network Therapeutics for Cancer (Ou)



Lung Cancer Clinical Trials

Single Mutation Driven Trials

UCI 17-90**

A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy (Ou)

**UCI 17-50

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumor (Ou)

UCI 16-96

A Phase 1 Study with Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors (Ou)

UCI 07-40

Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

